Prm256 - Adjustment for the Impact of Subsequent Therapies Not Available in Uk on Overall Survival (Os) in Castor Trial: A Subgroup Analysis in Second-Line (2l) Patients

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2373
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Impact of Second-Line Treatment on Overall Survival of Advanced Lung Adenocarcinoma Patients

2016English

Prm118 - Adjustment for Subsequent Therapies Received: The Impact on Outcomes of an Economic Model of Nivolumab+ipilimumab in First Line Renal Cell Carcinoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Figure 3: Survival Analysis of CELSR3 Expression in Terms of Overall Survival (OS).

English

Impact of Comorbidity on Overall Survival in Patients Surgically Treated for Renal Cell Carcinoma

Urology
Urology
2008English

Pre-Operative Tracheostomy Does Not Impact on Stomal Recurrence and Overall Survival in Patients Undergoing Primary Laryngectomy

European Archives of Oto-Rhino-Laryngology
MedicineOtorhinolaryngology
2012English

Increased Risk of Second Primary Hematologic and Solid Malignancies in Patients With Mycosis Fungoides: Impact on Overall Survival in Seer Registry

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

PDB21 Chart Audit and Budget Impact Analysis of Pasireotide Versus Second-Line Therapies in the Treatment of Cushing's Disease in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

The Impact of Increasing Dose on Overall Survival in Prostate Cancer

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2015English

Figure 5: Survival Curves for DEmRNAs That Are Associated With the Overall Survival (OS) of LUSC Patients.

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy